Neoadjuvant Doxorubicin/Cyclophosphamide Followed by Ixabepilone or Paclitaxel in Early Stage Breast Cancer and Evaluation of βIII-Tubulin Expression as a Predictive Marker

BACKGROUND. This randomized phase II trial was designed to compare the rate of pathologic complete response (pCR) induced by neoadjuvant cyclophosphamide plus doxorubicin (AC) followed by ixabepilone or paclitaxel in women with early stage breast cancer (BC). Expression of βIII-tubulin as a predicti...

תיאור מלא

שמור ב:
מידע ביבליוגרפי
Main Authors: Saura, Cristina, Tseng, Ling-Ming, Chan, Stephen, Chacko, Raju T., Campone, Mario, Manikhas, Alexy, Nag, Shona M., Leichman, Cynthia G., Dasappa, Lokanatha, Fasching, Peter A., Hurtado de Mendoza, Fernando, Symmans, W. Fraser, Liu, David, Mukhopadhyay, Pralay, Horak, Christine, Xing, Guan, Pusztai, Lajos
פורמט: Artigo
שפה:Inglês
יצא לאור: AlphaMed Press 2013
נושאים:
Academia-Pharma Intersect: Breast Cancer
גישה מקוונת:https://ncbi.nlm.nih.gov/pmc/articles/PMC3720631/
https://ncbi.nlm.nih.gov/pubmed/23853246
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1634/theoncologist.2013-0075
תגים: הוספת תג
אין תגיות, היה/י הראשונ/ה לתייג את הרשומה!

פריטים דומים